Fibronectin (Fn) is a major protein of blood and tissue that occurs in both soluble (plasma) and insoluble (tissueassociated) forms. This high-molecular-weight glycoprotein, with its many binding sites, is uniquely suited to function as a link between substances. Since its ability to bind staphylococci was first reported in 1978 (15), many bacteria have been shown to interact with Fn (3, 9, 17, 18, (23) (24) (25) . The interaction between Fn and bacteria is postulated to modulate mucosal surface colonization (1, 21) and may promote phagocytosis and reticuloendothelial clearance of invading organisms (11, 12, 22) . Since neonates show time-limited susceptibility to group B streptococcal (GBS) disease and also have physiologically low Fn levels (6, 10), we hypothesized that differential Fn binding could influence the invasive potential of GBS.
A previous study of the interaction of Fn with GBS (17), while suggesting a potential role for Fn in the pathogenesis of GBS, did not address the issue of strain or serotype variability among isolates. A disparity among GBS serotypes or strains within a given serotype in Fn binding might further elucidate the predilection of particular GBS strains to evade neonatal host defenses and cause invasive disease. In this study we examined the interaction of soluble Fn with a variety of GBS strains categorized by source and serotype and possible cell surface structures mediating binding.
MATERIALS AND METHODS
Fn purification and labeling. Fn was purified by the method of Engvall and Ruoslahti (8) as described by Verbrugh et al. (26) . All chemicals were purchased from Fisher Scientific Co. (Pittsburgh, Pa.) unless otherwise specified. Fresh citrated human plasma containing 0.2% sodium azide and 10 (19) . The specific activity of the labeled protein was -2,000 to 2,500 cpm/,ug. Functionally active [3H]Fn was isolated by repeat affinity chromatography, concentrated by precipitation with 50% ammonium sulfate, suspended in PBS-BSA (pH 7.4), dialyzed against the same, filtered (Millex-GV 0.22-p,m-poresize filter unit; Millipore Corp., Bedford, Mass.), and assayed for Fn. The final product was stored at -20°C until used in binding assays.
Preparation of IgG. Human sera containing a high level of antibody, as determined by a radioactive antigen binding assay (4, 14) , to the capsular polysaccharide of type Ia, II, or III GBS were chromatographed on a QAE-Sephadex A-50 column (Pharmacia Fine Chemicals, Piscataway, N.J.) equilibrated with 0.048 M ethylene diamine-0.073 M acetic acid buffer, pH 7 (13 For each experiment, isolates were subcultured onto blood agar plates, incubated at 37°C overnight, grown in THB at 37°C, and harvested at the log (2 to 4 h in unbuffered medium) or stationary (16 to 20 h) phase. Bacteria were collected by centrifugation (IEC Centra-FR; International Equipment Company, Needham Heights, Mass.) at 550 x g for 15 min at 4°C, washed once in 0.15 M NaCl and once in PBS containing 0.1% BSA, (pH 7.4), and resuspended in PBS-BSA to give concentrations of 0.5 x 109 to 1.5 x 109 CFU/ml. For selected experiments, bacteria were grown in the presence of either trypsin (2 mg/ml of THB; Sigma Chemical Co., St. Louis, Mo.) or neuraminidase type V (0.43 U/ml of THB; Sigma).
Opsonization of bacteria. Bacteria were incubated with purified IgG in a shaking water bath (Precision Scientific Group, Chicago, Ill.) for 45 min at 37°C. After centrifugation at 13,000 x g for 5 min (Fisher microcentrifuge model 235 B), the supernatant was discarded and the bacterial pellet was suspended in PBS-BSA for use in binding experiments. This method has previously been shown to effect efficient opsonization of bacteria as determined by a luminolenhanced chemiluminescent and phagocytic assay (2) . Selected isolates treated with either neuraminidase or trypsin were opsonized in the same manner and also tested.
Binding experiments. Binding experiments were performed in 1.5-ml polypropylene microcentrifuge tubes (West Coast Scientific, Inc., Emeryville, Calif.) which had been incubated with PBS-0.1% BSA (pH 7.4) overnight to minimize nonspecific Fn binding to the tubes. A 250-,lI volume of bacterial suspension was incubated with various concentrations of [3H]Fn (2.5 to 110 ,ug/ml) in a total volume of 500 ,ul in a shaking water bath at 37°C for 30 min. In selected experiments, a 500-,u volume of bacteria was used. Bacteria were pelleted by centrifugation at 13,000 x g for 5 min, washed three times with PBS-BSA, pelleted, and allowed to dry. The pellet was dissolved in 1 ml of Protosol (New England Nuclear Corp.); 10 ml of Liquifluor (New England Nuclear Corp.)-toluene (Fisher) was added; and the radio- (Fig. 1) (Table 2) .
A randomly selected group of GBS isolates were incubated with 300 ,ug of Fn per ml, a concentration chosen to approximate the adult human level. Under these conditions of Fn excess, S. aureus bound 4.4% of available radioactivity. Again, no significant binding to GBS could be demonstrated ( Table 2) .
Manipulation of assay conditions. We attempted to enhance Fn binding by manipulation of GBS assay conditions. In two experiments, each run in duplicate, 500 ,ul of bacteria (3) 0.4 (4) 0.4 (5) 0.2 (2) a NT, Nontypable. b 2 mg/ml of THB. c 0.42 U/ml of THB.
dType-specific IgG antibody concentration was ¢40 ,ug/ml in reaction mixture.
was incubated with a very low concentration of Fn (1.2 ,ug/ml), and the bacteria bound a mean of 3.7 and 4.1% of the available radioactivity, respectively. As previously described (17) , the Fn binding to S. aureus exhibited pH dependency. Binding was maximum at pH 6 (88% of available radioactivity bound). At pH 6, GBS bound 3% of the available radioactivity, higher than that seen at pH 4 (1.7%), 7.4 (0.7%), or 8 (0.5%).
Modification of surface antigenic components. Growth in the presence of trypsin (2 mg/ml of THB) of a nontypable strain and two type II strains known to possess the trypsinsensitive component of the c protein did not affect binding (Table 3) . Growth of type Ia and III strains in the presence of neuraminidase (0.43 U/ml) to cleave a portion of sialic acid residues (6) also did not alter binding. To examine the possible influence of serotype-specific IgG antibody, we tested preopsonized GBS. No enhancement of binding was found (Table 3) . To exclude the possibility that the uniformly low binding to GBS could represent an inhibitory phenomenon by the GBS, we incubated Fn with either S. aureus or GBS type Ia or III. Binding to the pellet was determined and found to be 47, 0.4, and 0.4%, respectively. Subsequently, each supernatant was incubated with S. aureus which bound 52, 56, and 68% of the available radioactivity, respectively. The newly added S. aureus bound Fn with the expected avidity regardless of its initial exposure to either S. aureus or GBS. This mitigates against an inhibitory effect by GBS on Fn or at least on the receptor for S. aureus.
Role of capsule in Fn binding. To further delineate the potential role of the GBS type-specific polysaccharide capsule in inhibiting binding with Fn, we tested the COH 31-15 mutant, lacking the type-specific capsule, and its parent strain, COH 31r/s. Both failed to bind Fn, each binding a mean of 0.4% of the available Fn in contrast to the 78% binding exhibited by S. aureus in the same experiment.
DISCUSSION
The preceding experiments indicate that regardless of source, serotype, or strain, GBS uniformly resist binding substantially to Fn. Such uniformity is unusual among grampositive organisms, in which strain-to-strain variability appears to be common (17, 23) . For example, although Fn binds to most staphylococci and promotes their association with neutrophils, there was no single species among the 10 examined by Switalski et al. (23) of binding among strains representing group A, C, and G streptococci. These investigators also detected minimal Fn binding to 16 strains of GBS, but neither a description of the isolates by source or serotype nor the growth conditions were specified. In view of the known strain-to-strain variability in binding among isolates of other species, we hypothesized that similar inconstancy might be seen among GBS and account for differences in virulence.
Understanding the interaction of Fn and GBS is potentially important. GBS rarely cause invasive disease in adults, although vaginal colonization is present in up to 30%o of adult women. It is attractive to postulate that the physiologically low levels of Fn occurring in neonates is one factor contributing to their susceptibility to invasive GBS disease. While there is no definite correlation between ability to bind Fn and bacterial virulence, significant alterations in Fn concentrations in plasma have been noted in a variety of conditions including sepsis. Enhancement of reticuloendothelial function in septic patients after the infusion of Fn-rich products has been reported (20) . The study of Hill and associates (11) was the first to show that Fn promoted the interaction of GBS with neutrophils and antibodies. In their rat model of GBS disease, Fn increased the protective effect of monoclonal and polyclonal IgG preparations against GBS (11) . Both this and a study by Jacobs et al. (12) (27) , is undoubtedly sensitive to the presence of additional host factors.
In conclusion, unlike most other tested gram-positive organisms, GBS 
